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The immune function within the tumor microenvironment has
become a prominent therapeutic target, with tumor-associated
macrophages (TAMs) playing a critical role in immune suppression.
We propose an 89Zr-labeled high-density lipoprotein (89Zr-HDL)
nanotracer as a means of monitoring response to immunotherapy.
Methods: Female MMTV-PyMT mice were treated with pexidarti-
nib, a colony-stimulating factor 1 receptor (CSF1R) inhibitor, to re-
duce TAM density. The accumulation of 89Zr-HDL within the tumor
was assessed using PET/CT imaging and autoradiography,
whereas TAM burden was determined using immunofluorescence.
Results: A significant reduction in 89Zr-HDL accumulation was ob-
served in PET/CT images, with 2.9% ± 0.3% and 3.7% ± 0.2%
injected dose/g for the pexidartinib- and vehicle-treated mice, re-
spectively. This reduction was corroborated ex vivo and correlated
with decreased TAM density. Conclusion: These results support
the potential use of 89Zr-HDL nanoparticles as a PET tracer to
quickly monitor the response to CSF1R inhibitors and other thera-
peutic strategies targeting TAMs.
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Breast cancer is the second leading cause of cancer-related
death for women in the United States. Mortality in breast cancer
results from the formation of metastases in organs such as the brain,
liver, lungs, and bone marrow (1). Although most patients do not
present with metastatic lesions in distant tissue on initial diagnosis,
1 in 3 women with node-negative and an even larger percentage of
those with node-positive breast cancer will eventually develop dis-
tant metastases (2). The standard of care for early- and late-stage
breast cancers includes chemotherapy, radiation therapy, or endocrine
therapy (3). Although the 5-y survival rate for breast cancer is near
90%, the rate significantly decreases to 30% in metastatic breast
cancer (4). An appreciable amount of research has described the
critical roles that the innate and adaptive immune system plays in
cancer development and progression (5,6). Immune checkpoint
blockade, engineered chimeric antigen receptor T cells, and other
drugs designed to modulate the activity and migration of innate
and adaptive immune cells have become focal points of preclinical
and clinical research (7).
The recruitment of myeloid cells, in particular macrophages, is
considered to be one of the earliest and most crucial phases in the
development of metastatic lesions (2). Macrophages exhibit dual
functionality in modulating immune response: classically activated
macrophages are proinflammatory, whereas alternatively activated
macrophages secrete cytokines that induce tissue repair and sup-
press immune function (8). The accumulation of macrophages
within the tumor and their shift toward an alternatively activated
phenotype results in signaling cascades that induce angiogenesis,
alter the extracellular matrix, and suppress adaptive immune response
(9–11). Therefore, tumor-associated macrophage (TAM) burden has
been correlated with rapid tumor growth, metastatic potential,
and poor patient prognosis (12).
Colony-stimulating factor 1 (CSF1) and its respective receptor
(CSF1R) play a key role in the recruitment and activation of
macrophages (13). There are numerous clinical trials exploring the
use of CSF1R inhibitors as a monotherapy or in combination
with other therapeutic strategies in various types of cancer (14).
Pexidartinib (PLX3397), a CSF1R inhibitor currently in phase 3
clinical trials, has shown promising results as a monotherapy and
in combination with immune checkpoint therapies (14). However,
traditional methods of evaluating patient response can provide
misleading results. Thus, physicians require approximately 3–4
mo to properly assess treatment efficacy in patients undergoing
immunotherapies (15).
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The affinity of high-density lipoprotein (HDL) particles for
macrophages has been well documented, and numerous formula-
tions have been engineered to noninvasively visualize macrophage
accumulation in a variety of inflammatory diseases such as
atherosclerosis, arthritis, and cancers using different imaging
modalities (16–20). Here, we explore the use of 89Zr-labeled
reconstituted HDL as a macrophage-targeted diagnostic tool that
might help clinicians more quickly and accurately assess the re-
sponse to anti-TAM immunotherapies. To evaluate the ability of
89Zr-HDL to noninvasively monitor TAM burden by PET, we
chose an aggressive transgenic mouse model of mammary adeno-
carcinoma: MMTV-PyMT (21). The biodistribution of 89Zr-HDL
nanoparticles, specifically the accumulation in the tumor, was
analyzed and compared in pexidartinib-treated and untreated
MMTV-PyMT mice (Supplemental Fig. 1; supplemental materials
are available at http://jnm.snmjournals.org).
RESULTS
Synthesis and Radiolabeling of HDL Nanoparticles
89Zr-labeled HDL nanoparticles were prepared following our
previously reported methods (Fig. 1A) (18). Deferoxamine-HDL
nanoparticles had a hydrodynamic diameter of 10.9 6 2.8 nm (n
5 3), as determined by DLS (Fig. 1B). 89Zr-HDL nanoparticles
were isolated in a 93% 6 6% (n 5 3) radiochemical yield and
greater than 99% radiochemical purity, as determined by radio–
high-performance liquid chromatography (Fig. 1C).
PET/CT Imaging and In Vivo Quantification of
89Zr-HDL Nanoparticles
To assess the ability of the 89Zr-HDL nanoparticles to act as a
macrophage tracer to monitor CSF1R inhibition, MMTV-PyMT
mice were treated with PLX3397 or vehicle for 5 d via daily oral
gavage. This particular strain of mice begins to spontaneously
develop mammary adenocarcinomas as early as 3 wk old (21).
At approximately 11 wk of age, when the mammary tumors had
grown to an average volume of 200 mm3, the treatment was
initiated. PLX3397 and vehicle were administered for 5
d based on previously reported results (13). The mice were then
given the 89Zr-HDL nanoparticles and imaged 24 h after injection.
89Zr-HDL uptake in tumors, determined noninvasively by drawing
volumes of interest over the entire tumor mass within the mammary
glands on the PET/CT images (Supplemental Fig. 2), was signifi-
cantly lower in PLX3397-treated mice than in controls (2.9% 6
0.3% vs. 3.7% 6 0.2% injected dose/g, P , 0.01; Fig. 2B).
Ex Vivo Quantification of 89Zr-HDL Nanoparticles and
Macrophage Burden
The mice were euthanized by CO2 asphyxiation immediately
after PET/CT imaging, and the tumors were harvested, frozen in
optimal-cutting-temperature compound, and sectioned for immu-
nofluorescence and autoradiographic analysis. Macrophage burden
was quantified through IBA-1 staining followed by immunofluo-
rescence imaging, with observed macrophage densities of 3.1% 6
0.9% and 12.3% 6 6.4% IBA-1 positive cells for PLX3397- and
vehicle-treated mice, respectively (P , 0.05; Fig. 3B). In addition,
the 89Zr-HDL nanoparticle accumulation was assessed using autora-
diography and normalized to the injected dose. This analysis
showed a significantly lower radioactivity deposition in tumors
from PLX3397-treated mice than in controls (11.3 6 1.2 vs. 15.8 6
3.2 maximum arbitrary unit per injected dose, P, 0.05; Fig. 3C). The
differences in nanoparticle accumulation, as observed in both in
vivo and ex vivo analyses, correlate with the changes in TAM
density as a result of CSF1R inhibition (22,23).
DISCUSSION
The purpose of this study was to evaluate the use of an 89Zr-
HDL nanoparticle as a macrophage tracer that might provide cli-
nicians an additional tool to assess the effect of CSF1R inhibitors
and other immunotherapies on TAMs. The intricate role TAMs
play in altering immune function within the tumor microenviron-
ment has made them of particular interest as targets in numerous
therapeutic studies (11,14). The combination of therapeutic strat-
egies altering both the innate and the adap-
tive immune system is promising; however,
there are currently no accepted biomarkers
that can accurately predict immunotherapy
efficacy (7). Traditional methods such as
RECIST can be misleading when evaluat-
ing patients undergoing immunotherapy,
because tumor size can vary with changes
in immune cell infiltration (15,24,25). This
phenomenon, known as pseudoprogression,
prevents physicians from contemporane-
ously assessing therapeutic responses, delay-
ing conclusive evaluation to at least 3–4 mo
after treatment initiation (26,27). Therefore, a
significant clinical need exists to develop
methods that can quickly and accurately
monitor the effect of these therapies on
TAM populations.
The observed 89Zr-HDL uptake assessed
through in vivo PET/CT and ex vivo auto-
radiography analyses showed significant
differences between PLX3397- and vehi-
cle-treated cohorts. The excised tumors in-
cluded areas of high fat content, as they
FIGURE 1. Synthesis and characterization of 89Zr-HDL nanoparticles. (A) Radiolabeling synthe-
sis conditions for formation of 89Zr-HDL nanoparticles. (B) Dynamic light scattering analysis of
HDL nanoparticles exposed to labeling conditions. (C) Radio–high-performance liquid chroma-
tography analysis illustrating chemical and radiochemical purity of 89Zr-HDL nanoparticles.
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were collected from the mammary fat pad, making it difficult to
draw regions of interest that included only the cancer cells and
stroma. When the activity was averaged over the drawn region of
interest, a decrease in nanoparticle accumulation as a result of
PLX3397 treatment was observed (Supplemental Fig. 3B). How-
ever, the differences in accumulation between the two groups were
not statistically significant. Thus, the maximum accumulated activ-
ity within each tissue section was also analyzed to reduce the
impact of areas with high fat content and very low nanoparticle
accumulation on the analysis. The resulting data for the excised
tumors showed statistically significant differences in 89Zr-HDL
nanoparticles between the two cohorts (Fig.
3C). The immunofluorescence analysis pro-
vided evidence of effective reduction in mac-
rophage density within the tumor as a result
of the CSF1R inhibition. In addition, whereas
IBA-1 is a prominently used macrophage
stain in immunofluorescence, its expression
is not exclusive to macrophages (28). IBA-1
can also appear on other myeloid cells such
as monocytes and some lymphocytes. CSF1R
inhibition, using PLX3397, was shown to
be ineffective at reducing infiltration of mono-
cytes and dendritic cells in the MMTV-PyMT
mouse model (13). Thus, any IBA-1 staining
associated with these cell populations may
have led to smaller observed differences in
TAM populations between the PLX3397-
and vehicle- treated cohorts (13). Although
there was considerable variation in TAM
density between tissue sections, illustrating
the highly heterogeneous nature of the tu-
mor microenvironment, the differences between the PLX3397- and
vehicle-treated cohorts remained statistically significant (Fig. 3B).
A correlation between macrophage density and 89Zr-HDL nanopar-
ticle accumulation was observed in both the PET/CT and the ex vivo
analyses (Supplemental Fig, 3). As is apparent in the PET/CT im-
ages, there was significant accumulation of the 89Zr-HDL nanopar-
ticles within the liver (Fig. 2A). Thus, whereas the tracer is
ostensibly capable of imaging tumors in most tissues, the 89Zr-
HDL nanoparticles would likely be unable to delineate metastases
within the liver. The observed differences in nanoparticle accumu-
lation, assessed using both in vivo PET/CT imaging and ex vivo
autoradiography, were the result of modula-
tions in TAM density as a consequence of
treatment with the CSF1R inhibitor, pexi-
dartinib. As observed in the ex vivo anal-
ysis, the macrophage content and nanoparticle
accumulation was very heterogeneous. The
use of PET/CT was able to overcome this
heterogeneity, as 89Zr-HDL nanoparticle
accumulation provided a quantifiable means
of evaluating TAM content over the entire
tumor area. Thus, the use of 89Zr-HDL nano-
particles as a macrophage-avid PET tracer
provides a noninvasive tool to quantita-
tively assess overall macrophage burden
and could provide clinicians the means
to quickly and accurately assess response
to macrophage-targeted therapies.
CONCLUSION
The data presented herein show that
89Zr-HDL tumor uptake correlates with
macrophage density within the tumor mi-
croenvironment. The statistically signifi-
cant modulation in TAM burden, as a
result of PLX3397 treatment, could be ob-
served by quantifiable differences in 89Zr-HDL
nanoparticle uptake using PET imaging within
1 wk of initiating treatment. Thus, 89Zr-HDL
FIGURE 3. Ex vivo quantification of 89Zr-HDL nanoparticles correlates with tumor-associated
macrophage density. (A) Hematoxylin and eosin (H&E), autoradiography, and immunofluores-
cence images of tumors excised from MMTV-PyMT mice. (B) Quantification of TAMs represented
as percentage of total cells. (C) Maximum accumulation of 89Zr-HDL nanoparticles within region
of interest (ROI) on autoradiography; activity was normalized to injected dose for each mouse.
A.U./ID 5 arbitrary unit per injected dose. *P , 0.05.
FIGURE 2. In vivo analysis of 89Zr-HDL nanoparticles, visualized by PET/CT, showing reduced
accumulation in mice treated with PLX3397. (A) PET/CT images representing 89Zr-HDL nano-
particle distribution. (B) Quantification of 89Zr-HDL nanoparticle uptake determined by drawing
volume of interest (VOI) over entire tumor burden. ID 5 injected dose. **P , 0.01.
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nanoparticles are a promising tool that could potentially help
physicians more rapidly and accurately determine the early re-
sponse to therapies targeting the immunosuppressed tumor
microenvironment.
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KEY POINTS
QUESTION: Is it possible to utilize a macrophage-selective 89Zr-
HDL nanoparticle as a PET imaging agent to monitor the response
to a CSF1R inhibitor?
PERTINENT FINDINGS: In a murine breast cancer model we
observed significant differences in 89Zr-HDL nanoparticle uptake
with 3.7 ± 0.2 %ID/g and 2.9 ± 0.3 %ID/g for the vehicle- and
pexidartinib-treated mice, respectively. This reduction in nano-
particle uptake correlated with decreased tumor-associated
macrophages as a result of CSF1R inhibition.
IMPLICATIONS FOR PATIENT CARE: The results in this manu-
script provide evidence supporting the possible translation of the
89Zr-HDL nanoparticles as a means of monitoring CSFR1 inhibi-
tion and potentially other therapeutic strategies that modulate
tumor-associated macrophage activity.
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